The expedition of the approval of new drugs is a dilemma that causes major ethical conflict in the pharmaceutical field. The issue arises when terminally ill patients with a short life expectancy wish to access new medication that is not yet available on the market due to lack of approval from the Food and Drug Administration (FDA). Using the ethical framework of virtue ethics, some believe that patients should have the right to express their autonomy and take the risk of using unapproved drugs. In the light of this argument, some organizations have created shorter trials that allow people…